Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Circassia, a specialty biopharmaceutical company, has acquired the US, Canadian and Japanese development and commercialization rights to dopexamine from Ipsen, an international speciality pharmaceutical company.
Subscribe to our email newsletter
Circassia has also entered into agreements with pharmaceutical manufacturers Excella and Hospira to establish a commercial-scale supply chain for the product. Circassia is developing dopexamine in a new indication as an integral part of proprietary structured protocols designed to improve patient recovery following a range of high-risk surgeries.
This novel approach, named ToleroCare, which Circassia has recently patented, combines the use of dopexamine with the administration of intra-venous fluids to improve tissue oxygenation levels during the recovery period after surgery. The precise use of fluids and dopexamine is based on carefully defined parameters such as heart stroke volume and oxygen delivery index.
Dopexamine is a beta2 adrenoceptor and dopamine receptor agonist, which is approved in Europe in indications related to heart failure.
Steve Harris, CEO of Circassia, said: “Dopexamine provides Circassia with a further Phase II clinical-stage development program that fits well with our outsourced business model. By establishing a commercial-scale supply chain for dopexamine, we are well positioned to rapidly progress ToleroCare to market.”